title: Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
abstract: BACKGROUND
  The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC).
  
  
  METHODS
  Patients with progressive AIPC received 90 mg/m2 paclitaxel by 1-hour intravenous infusion weekly for 3 weeks, followed by a 1-week treatment rest. Patients received 140 mg EMP orally 3 times daily on the day before, the day of, and the day after paclitaxel administration. Patients received 1 mg warfarin daily to prevent thromboembolism.
  
  
  RESULTS
  Sixty-six patients with progressive AIPC received treatment at 29 centers. Forty-two percent of patients had a 50% decline in prostate-specific antigen (PSA; 95% confidence interval [CI], 30-54%). For 26 patients with bidimensionally measurable disease, the objective response rate was 15% (95% CI, 1-30%). The median time to disease progression was 6.3 months, and the median time to PSA progression was 11.4 months. The median survival period was 15.6 months. Grade 3-4 toxicities were uncommon and included thromboembolism (8%), anemia (3%), neutropenia (3%), and peripheral neuropathy (2%). There was one treatment-related death.
  
  
  CONCLUSIONS
  This regimen of EMP plus weekly paclitaxel was an active and well tolerated treatment for patients with AIPC.
authors.affiliation: Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. djv@mail.med.upenn.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Vaughn
authors.forename: Archie W
authors.initials: AW
authors.lastname: Brown
authors.forename: W Graydon
authors.initials: WG
authors.lastname: Harker
authors.forename: Sang
authors.initials: S
authors.lastname: Huh
authors.forename: Lance
authors.initials: L
authors.lastname: Miller
authors.forename: David
authors.initials: D
authors.lastname: Rinaldi
authors.forename: Fairooz
authors.initials: F
authors.lastname: Kabbinavar
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D004961:Estramustine; D017239:Paclitaxel